Related references
Note: Only part of the references are listed.The development of evidence-based European guidelines on the management of depression in palliative cancer care
Lauren Rayner et al.
EUROPEAN JOURNAL OF CANCER (2011)
Harnessing the internet cloud for managing drug interactions with chemotherapy regimens in patients with cancer suffering from depression
Kevin Yi-Lwern Yap et al.
ACTA ONCOLOGICA (2010)
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
Catherine M. Kelly et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Interactions Between Tamoxifen and Antidepressants via Cytochrome P450 2D6
Julie Eve Desmarais et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment
Y. Xu et al.
ANNALS OF ONCOLOGY (2008)
Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy
Kazuma Kiyotani et al.
CANCER SCIENCE (2008)
Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer
Masako Okamura et al.
PSYCHO-ONCOLOGY (2008)
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
Werner Schroth et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions
Abdo Haddad et al.
SUPPORTIVE CARE IN CANCER (2007)
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment
Silvana Borges et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Detection and treatment of depressive and anxiety disorders among cancer patients: Feasibility and preliminary findings from a liaison service in an oncology division
M. Pasquini et al.
DEPRESSION AND ANXIETY (2006)
Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: An in vitro study
RS Obach et al.
DRUG METABOLISM AND DISPOSITION (2005)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants
C Puozzo et al.
CLINICAL PHARMACOKINETICS (2005)
Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects
WE Evans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Depression as a prognostic factor for breast cancer mortality
K Hjerl et al.
PSYCHOSOMATICS (2003)
Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: Mechanism of drug interaction between TCAs and phenytoin
JG Shin et al.
DRUG METABOLISM AND DISPOSITION (2002)
Depression and functional status as predictors of death among cancer patients
M Stommel et al.
CANCER (2002)
Share Paper
